Celea Therapeutics Raises $180M for IPF Drug Development

Celea Therapeutics has successfully closed a substantial $180 million financing round, injecting significant capital to propel its investigational drug, deupirfenidone (LYT-100), towards becoming a new standard of care for idiopathic pulmonary fibrosis (IPF). This funding marks a critical step in advancing the drug through pivotal clinical development, aiming to address a significant unmet need in a disease characterized by progressive lung scarring and limited therapeutic options.

The substantial investment saw participation from prominent financial entities, including RA Capital Management, Leaps by Bayer, and Celea's founding entity, PureTech Health. The round was further bolstered by the involvement of a major U.S.-based healthcare-focused fund and a leading sovereign wealth fund, underscoring strong investor confidence in deupirfenidone's potential. This broad support base highlights the perceived value and strategic importance of Celea's pipeline within the competitive biopharmaceutical sector.

Central to the funding's allocation is the planned initiation of the SURPASS-IPF Phase 3 trial, slated for early Q3 2026. This trial is designed as the first head-to-head Phase 3 study in IPF, directly comparing deupirfenidone against pirfenidone, a currently approved therapy. The study will evaluate deupirfenidone at 825 mg three times daily against pirfenidone at 801 mg three times daily in adult IPF patients not receiving background therapy. The primary endpoint focuses on the change in absolute forced vital capacity at 52 weeks, aiming to demonstrate superiority.

Deupirfenidone, a deuterated derivative of pirfenidone, represents a next-generation antifibrotic agent. Its development is supported by promising data from the Phase 2b ELEVATE IPF trial, which indicated a potential to stabilize lung function decline over at least 26 weeks as a monotherapy, while maintaining a favorable safety and tolerability profile. Early indications from an open-label extension suggest these benefits may persist for up to 52 weeks, providing a compelling rationale for the upcoming pivotal trial.

Idiopathic pulmonary fibrosis is a devastating, rare condition affecting an estimated 100,000 people in the U.S. alone, with a median survival of just two to five years post-diagnosis. The lack of a cure and the limitations of existing treatments underscore the urgent need for innovative therapies. Deupirfenidone's Orphan Drug Designation from both the U.S. FDA and the European Commission further emphasizes its potential to address this critical medical challenge.

The successful fundraising positions Celea Therapeutics, a clinical-stage biopharmaceutical company focused on respiratory diseases, to execute its ambitious development plan. CEO Sven Dethlefs, Ph.D., expressed gratitude for the investor support, emphasizing the potential for deupirfenidone to offer meaningful improvements for IPF patients. Similarly, Laura Stoppel, Ph.D., Partner at RA Capital Management, highlighted the differentiated opportunity presented by the SURPASS-IPF trial and Celea's experienced team in potentially reshaping the IPF treatment paradigm.